Stem Cell Therapy Shows Promise for Type 1 Diabetes
A clinical trial finds that zimislecel infusion helps most patients eliminate the need for daily insulin injections.
Updated on Oct. 28, 2026 in Diabetes
Live Poll
Do you trust that new medical therapies can significantly reduce the emotional burden of managing diabetes?
A clinical trial of the stem cell-derived therapy zimislecel successfully reduced hypoglycemia fear and diabetes distress in 12 adults with type 1 diabetes. Most participants reached target blood sugar levels and were able to cease exogenous insulin use.
Why it matters
This therapy aims to restore the body's natural ability to regulate glucose, potentially transforming long-term disease management. By reducing the reliance on external insulin, the treatment could significantly alleviate the psychological and physical burdens of living with type 1 diabetes.
All 12 participants reduced HbA1c levels to below 7% and achieved a 93.3% time in range for glucose levels at one year. Patients also reported a 52.3-point reduction in hypoglycemic fear scores and a 1.5-point drop in overall diabetes distress.
The players
University of Pennsylvania
Researchers from this institution led the clinical investigation into the efficacy of zimislecel.
The details
Zimislecel is administered as a single infusion designed to restore pancreatic islet cell function. To ensure the success of the transplant, participants must undergo an immunosuppressive regimen to prevent the body from rejecting the new cells.
Timeline
2025: Phase 1 and 2 data was presented at the ADA Scientific Sessions.
90 days: Time in range for glucose levels rose to 76.1%.
180 days: Time in range for glucose levels rose to 88.3%.
1 year: Time in range for glucose levels reached 93.3%.
Health Landscape
The study marks a significant progression in islet cell therapy research, moving beyond insulin delivery toward biological restoration. It follows the trajectory of the FORWARD-VX-880-101 clinical trial by providing updated evidence on long-term glycemic control and patient-reported outcomes.
The success of this trial suggests a future where patients may no longer require daily insulin injections to manage their condition. However, participants must currently commit to immunosuppressive medication, which presents its own long-term health considerations.
The takeaway
This breakthrough illustrates the potential for stem cell therapies to grant patients greater autonomy over their glucose levels. Future researchers will focus on optimizing immunosuppression to maximize these quality-of-life improvements while minimizing side effects.
Further reading
Learn more about the latest advancements in the field of Diabetes.
Source note: This article includes information reported by Healio.
Live Poll
Do you trust that new medical therapies can significantly reduce the emotional burden of managing diabetes?
